Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK.

ABSTRACT:

Background

Since receiving a positive recommendation in England, Wales and Scotland, tocilizumab (TCZ) is one of the options available to clinicians for the treatment of rheumatoid arthritis (RA) patients in the UK.

Objective

The objective of this study was to evaluate the cost effectiveness of adding TCZ to the current treatment sequence of RA patients from a UK payer's perspective over a patient lifetime horizon.

Methods

An individual sampling model was developed to synthesise all clinical and economic inputs. Two scenarios were explored separately: patients contraindicated to methotrexate (MTX) and those MTX tolerant. For each scenario, the analysis compared three strategies. The standard of care (SoC) strategy included a sequence of the most commonly prescribed bi

SUBMITTER: Diamantopoulos A 

PROVIDER: S-EPMC4113684 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature